MuSK-CAART

N/A

Report date: 2022/11/04 09:27:27

Base Information

Drug NameMuSK-CAART
Drug Alias NameAutologous Muscle-Specific tyrosine Kinase Autoantibody Receptor T cells (MuSK-CAART)MuSK-CAART
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityMuscle, skeletal receptor tyrosine-protein kinase agonists +[4] 
TargetsMuscle, skeletal receptor tyrosine-protein kinase
Therapy Area/IndicationsMyasthenia Gravis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of PennsylvaniaCabaletta Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesCabaletta Bio Inc
Inactive CompaniesN/A
Active IndicationsMyasthenia Gravis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A